Multiple Sclerosis Clinical Research Trials

Birmingham : Alabama Neurology Associates

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Birmingham : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Cullman : North Central Neurology Associates, PC

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Cullman : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Cullman : North Central Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Cullman : Teva Investigational Site 10329

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Phoenix : St. Joseph’s Hospital and Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Gilbert : Neurological Physicians of Arizona/Clinical Research Advantage

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Gilbert : Neurological Physicians of Arizona/Clinical Research Advantage

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Gilbert : Synthon investigational site 111

Efficacy and Safety of GTR in Comparison to Copaxone®

Gilbert : Osmotica Study Site

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Glendale : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Phoenix : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Phoenix : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Phoenix : St. Joseph's Hospital Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Sun City : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tempe : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tucson : NSS Clinical Research, LLC

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Tucson : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tucson : Northwest NeuroSpecialists, PLLC

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, PLLC

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Tucson : NSS Clinical Research, LLC

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, LLC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Berkeley : Jordan Research and Education Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Los Angeles : University of Southern California - Keck School of Medicine

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Berkeley :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Berkeley : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Berkeley : Alta Bates Summit Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Berkeley : Alta Bates Summit Medical Center, The Research and Education Development Institute

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Downey : Synthon investigational site 139

Efficacy and Safety of GTR in Comparison to Copaxone®

Fresno :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Fresno : Victoria Walton, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Fullerton : Fullerton Neurology and Headache Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Irvine : Synthon investigational site 112

Efficacy and Safety of GTR in Comparison to Copaxone®

La Jolla : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Long Beach : Collaborative Neuroscience Network, Inc.

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Long Beach : Synthon investigational site 119

Efficacy and Safety of GTR in Comparison to Copaxone®

Long Beach : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Los Angeles : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Los Angeles : Keck School of Medicine of the University of Southern Calfornia

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Relapsing Remitting Hispanic Multiple Sclerosis Forms

Los Angeles : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Los Angeles : USC

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Newport Beach : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newport Beach : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newport Beach : Multiple Sclerosis Center of California & Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Oceanside : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Orange : University of California, Irvine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Sacramento : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Sacramento : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Sacramento : Sutter Institute for Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

San Diego : Coordinated Clinical Research

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

San Francisco : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

San Francisco : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Francisco : University of California, San Francisco

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

San Francisco : University of California San Francisco

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Temecula : Viking Clinical Research Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Torrance : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Boulder : Alpine Clinical Research Center

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)

Boulder : Alpine Clinical Research Center

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS) who have had a documented relapse in the last year

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

Aurora : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Aurora : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Aurora : University of Colorado

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Boulder : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Boulder : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Centennial : Teva Investigational Site 10334

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Denver : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Denver : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Englewood : Colorado Neurological Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Fort Collins : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Fort Collins : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Fort Collins : Teva Investigational Site 10332

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

New London : Coastal Connecticut Research, LLC

Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?

Derby : Multiple Sclerosis Treatment Center

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Derby : Multiple Sclerosis Treatment Center

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Derby : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Fairfield : Synthon investigational site 134

Efficacy and Safety of GTR in Comparison to Copaxone®

Hartford : The Mandell Center for Multiple Sclerosis

Assessing Tolerability of Avonex Intramuscular Injections

New Haven : Institute for Neurodegenerative Disorders

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

New London : Coastal Connecticute Research, LLC

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

New London : Coastal Connecticute Research, LLC

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

New London : Synthon investigational site 124

Efficacy and Safety of GTR in Comparison to Copaxone®

Newark : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Newark : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newark : Christiana Care Health Services

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Washington : Georgetown University Hospital

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Washington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Washington : Georgetown University Hospital

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Washington : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Washington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tampa : Axiom Clinical Research of Florida

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis

Atlantis : Novartis Investigative Site

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Bradenton : Bradenton Research Center, Inc.

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Bradenton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bradenton : Bradenton Research Center, Inc.

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Bradenton : Osmotica Study Site-110

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Bradenton : Brandenton Neurology, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Gainesville : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Hollywood : Sunrise Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Jacksonville : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Jacksonville : University of Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Maitland : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maitland : Synthon investigational site 114

Efficacy and Safety of GTR in Comparison to Copaxone®

Maitland : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Maitland : Neurology Associates, PA

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Maitland : Neurology Associates, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Miami : Advanced Medical Pain Management & Research Clinic

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Miami : Advanced Medical Pain Management & Research Clinic

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Miami : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Naples : Collier Neurologic Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

North Palm Beach : Laszlo J. Mate, MD

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Orlando : Neurological Services of Orlando

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Ormond Beach : Neurology Associates of Ormond Beach

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Ormond Beach : Neurology Associates of Ormond Beach

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Ormond Beach : Osmotica Study Site-119

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Ormond Beach : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Ormond Beach : Neurology Associates of Ormond Beach

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ormond Beach : Neurology Associates of Ormond Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Pompano Beach : Osmotica Study Site-120

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Pompano Beach : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Pompano Beach : Neurological Associates

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pompano Beach : Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Port Charlotte : Synthon investigational site 120

Efficacy and Safety of GTR in Comparison to Copaxone®

Port Orange : Progressive Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Sarasota : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sarasota : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Sarasota : Roskamp Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

St. Petersburg : Suncoast Neuroscience Associates, Inc.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

St. Petersburg : Teva Investigational Site 10341

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Sunrise : Synthon investigational site 130

Efficacy and Safety of GTR in Comparison to Copaxone®

Tallahassee : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tallahassee : AMO Corporation

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Tampa : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampa : Synthon investigational site 115

Efficacy and Safety of GTR in Comparison to Copaxone®

Tampa : Osmotica Study Site-109

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Tampa : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tampa : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Tampa : University of South Florida

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Tampa : Teva Investigational Site 10323

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Vero Beach : Geodyssey Research, LLC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Vero Beach : MS Center of Vero Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Vero Beach : Vero Beach Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

West Palm Beach : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Weston : Cleveland Clinic Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Atlanta : NeuroTrials Research

Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.

Atlanta : Neurotrials Research, Inc.

Multiple Sclerosis

Atlanta : Emory University

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Atlanta : Shepherd Center

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Atlanta : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Atlanta : Shepherd Center

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Atlanta : Emory University

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Atlanta : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Atlanta : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Atlanta : Shepard Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Atlanta : Shepherd Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Decatur : Neurostudies

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Honolulu : Leo Maher, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Elk Grove Village : Alexian Brothers Hospital Network

A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).

Flossmoor : South Suburban Neurology

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Barrington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Champaign : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Chicago : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Chicago : Rush-Presbyterian St. Luke's Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Chicago : University of Chicago

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

Elk Grove Village : Synthon investigational site 107

Efficacy and Safety of GTR in Comparison to Copaxone®

Evanston : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Flossmoor : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Flossmoor : South Suburban Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lake Barrington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lake Barrington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lille Cedex : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Northbrook : Synthon investigational site 132

Efficacy and Safety of GTR in Comparison to Copaxone®

Northbrook : Osmotica Study Site-126

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Northbrook : Consultants in Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Peoria : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Peoria : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Anderson : Community Clinical Research Center

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis (PREFERMS)

Fort Wayne : Osmotica Study Site-108

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Indianapolis : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Indianapolis : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Indianapolis : Josephson Wallack Munshower Neurology, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Indianapolis : Josephson Wallack Munshower Neurology, PC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Merrillville : Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Des Moines : Mercy Ruan Neurology Clinic Res Ct.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

West Des Moines : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Lenexa : MidAmerica Neuroscience Research Foundation DBA: Rowe Neurology Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Kansas City : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kansas City : Synthon investigational site 118

Efficacy and Safety of GTR in Comparison to Copaxone®

Kansas City : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Kansas City : University of Kansas Medical Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Lenexa : Rowe Neurology Institute

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Lenexa : Rowe Neurology Institute

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Lenexa : Osmotica Study Site-116

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Lenexa : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Lenexa : MidAmerica Neuroscience Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lenexa : Mid America Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lenexa : Teva Investigational Site 10348

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Overland Park : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Topeka : Precise Clinical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Topeka : Cotton O'Neil Clinical Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lexington : University of Kentucky Chandler Medical Center

Help us to make progress in Secondary Progressive MS

Lexington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lexington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lexington : Associates in Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lexington : Associates in Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Louisville : Norton Neurology MS Services

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Louisville : Norton Neurology MS Services

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Louisville : Synthon investigational site 140

Efficacy and Safety of GTR in Comparison to Copaxone®

Louisville : University of Louisville (recruiting nationwide)

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Louisville : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Louisville : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Louisville : Norton Healthcare, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Hammond : ECommunity Research, LLC

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients With relapsing-remitting multiple sclerosis

Shreveport : Louisiana State University

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Hammond : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Baltimore : University of Maryland

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Baltimore : Johns Hopkins Medicine Updated

A randomized controlled trial of vitamin D supplementation in multiple sclerosis

Baltimore : Johns Hopkins

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Baltimore : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Baltimore : Johns Hopkins

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Baltimore : Osmotica Study Site-124

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Baltimore : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Baltimore : Johns Hopkins University School of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Baltimore : University of Maryland

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Baltimore : Johns Hopkins University

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Bethesda : Bethesda Neurology, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Boston : Brigham Women’s Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

New Bedford : Novex Clinical Research, LLC

Multiple Sclerosis

Boston : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Boston : Beth Israel Deaconess Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Boston : Caritas St. Elizabeth's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Boston : Saint Elizabeth's Medical Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Brookline : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Burlington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cambridge : Novartis Investigative Site

Pregnancy Registry Trial

Cambridge : Outcome Sciences, Inc

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Lexington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Milford : Milford Regional Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Springfield : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Springfield : Springfield Neurology Associates, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Worcester : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Worcester : Fallon Clinic at Worcester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Ann Arbor : Michigan Head-Pain & Neurological Institute

Clinical Trial for the treatment of spasticity in Patients with MS

Ann Arbor : Michigan Head-Pain & Neurological Institute

Clinical Trial for the treatment of spasticity in Patients with MS

Bingham Farms : QUEST Research Institute

Multiple Sclerosis Spasticity Study

Ann Arbor : Osmotica Study Site-101

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Clinton Twp : Michigan Neurology Associates, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Detroit : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Detroit : Wayne State University

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Detroit : Henry Ford Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

East Lansing : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Novi : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Traverse City : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Minneapolis : University of Minnesota

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Edina : Minneapolis Clinic of Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Golden Valley : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Golden Valley : Synthon investigational site 103

Efficacy and Safety of GTR in Comparison to Copaxone®

Columbia : University of Missouri Department of Physical Medicine and Rehabilitation

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Columbia : University of Missouri Department of Physical Medicine and Rehabilitation

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Kansas City : Saint Luke's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Springfield : St.John's Research Institute, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

St. Louis : Washington University (John L. Trotter MS Center)

Ampyra for Optic Neuritis in MS

St. Louis : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Great Falls : Advanced Neurology Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Great Falls : Benefis Physician Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lincoln : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lincoln : Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Omaha : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lebanon : Dartmouth Hitchcock Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Lebanon : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Marlton : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Newark : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newark : UMDNJ

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Princeton : GE Healthcare

Assess Safety, Bio-distribution, Dosimetry, and Optimize Imaging Protocol of GEH120714 (18F) Injection, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)

Teaneck : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Buffalo : Jacobs Neurological Institute Buffalo General Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Mineola : Winthrop University Hospital Clinical Trials Center

Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis

New York : Judith Jaffe Multiple Sclerosis Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Albany : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Albany : Albany Medical Center Hospital

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Albany : Neurological Associates of Albany, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Amherst : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Johnson City : Osmotica Study Site-115

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Latham : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Latham : Empire Neurology, PC

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Latham : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Latham : Empire Neurology, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

New York : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

New York : Osmotica Study Site-125

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

New York : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

New York : NYU-Hospital for Joint Diseases

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

New York : Mount Sinai School of Medicine

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Patchogue : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Patchogue : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Patchogue : South Shore Neurologic Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Plainview : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Plainview : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Plainview : Island Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Plainview : Island Neurological Assoicates, PC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Rochester : University of Rochester

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Rochester : University of Rochester

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Rochester : University of Rochester

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

Rochester : University of Rochester

Memantine for Spasticity in MS Patients

Rochester : University of Rochester

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Rochester : University of Rochester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Stony Brook : Stony Brook University

Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

Stony Brook : SUNY at Stony Brook

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Stony Brook : University Hospital and Medical Center Stony Brook New York

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

White Plains : Burke Rehabilitation Hospital

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

White Plains : Burke Rehabilitation Hospital

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

White Plains : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Chapel Hill : University of North Carolina

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Charlotte : PMG Research of Charlotte Updated

Does your Multiple Sclerosis cause muscle stiffness or muscle spasms?

Charlotte : PMG Research of Charlotte

Have you experienced greater disability from your Multiple Sclerosis (MS)?

Charlotte : PMG Research of Charlotte

Multiple Sclerosis (MS) Research Opportunity

Charlotte : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Concord : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Winston-Salem : PMG Research of Winston-Salem

Does your Multiple Sclerosis keep you from walking comfortably?

Winston-Salem : PMG Research of Winston-Salem Updated

Have you been diagnosed with a relapsing form of Multiple Sclerosis?

Advance : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Advance : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Asheville : Novartis Investigative Site

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Chapel Hill : University of North Carolina at Chapel Hill Department of Neurology

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Chapel Hill : University of North Carolina at Chapel Hill Department of Neurology

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Charlotte : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlotte : Synthon investigational site 125

Efficacy and Safety of GTR in Comparison to Copaxone®

Charlotte :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Charlotte : Osmotica Study Site-106

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Charlotte : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Charlotte : Osmotica Study Site

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Charlotte : Carolinas Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

High Point : Cornerstone Neurology

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Raleigh : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Raleigh : Synthon investigational site 141

Efficacy and Safety of GTR in Comparison to Copaxone®

Raleigh :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Wilmington : Osmotica Study Site

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Winston-Salem : PMG Research of Winston-Salem

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Winston-Salem : PMG Research of Winston-Salem

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Winston-Salem : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Winston-Salem : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Winston-Salem : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Grand Forks : Altru Health System/Altru Clinic-Main

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Grand Forks : Altru Health System/Altru Clinic-Main

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Grand Forks : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Akron : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Akron :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Akron : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Bellevue : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Bellevue : Teva Investigational Site 10309

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Cincinnati : Osmotica Study Site-131

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Cleveland : Synthon investigational site 106

Efficacy and Safety of GTR in Comparison to Copaxone®

Cleveland :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Cleveland : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Cleveland : Cleveland Clinic Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Columbus : The Ohio State University Medical Center

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Columbus : The Ohio State University Medical Center

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Columbus : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Columbus : Teva Investigational Site 10317

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Dayton : Synthon investigational site 135

Efficacy and Safety of GTR in Comparison to Copaxone®

Dayton : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Dayton : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Dayton : Neurology Specialists, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Dayton : Neurology Specialists, Inc

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Gahanna : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Uniontown : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Uniontown : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Oklahoma City : Lynn Health Science Institute

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Oklahoma City : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oklahoma City : Lynn Health Science Institute

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Oklahoma City : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Oklahoma City : Oklahoma Medical Research Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tulsa : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Eugene : Clinical Trials of America, Inc

Male and female aged 18-65 years, have you been diagnosed with multiple sclerosis?

Portland : Providence St. Vincent Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Clackamas : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Corvallis : The Corvallis Clinic, P.C.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Medford : Providence Medical Group - Medford

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Portland : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Portland : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Portland : Providence Multiple Sclerosis Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Portland : Providence St. Vincent Medical Center - Northwest MS Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Abington : Synthon investigational site 132

Efficacy and Safety of GTR in Comparison to Copaxone®

Abington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Altoona : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Greensburg : Westmoreland Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Hershey : Penn State University College of Medicine/MS Hershey Medical Center

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Indiana : Synthon investigational site 109

Efficacy and Safety of GTR in Comparison to Copaxone®

Philadelphia : Thomas Jefferson University

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Philadelphia : Thomas Jefferson University

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Philadelphia : Drexel University College of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Philadelphia : University of Pennsylvania Health System

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Pittsburgh : Osmotica Study Site-127

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Pittsburgh : Research Protocol Management Solutions

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Wilkes-Barre : Geisinger Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Providence : The Neurology Foundation, Inc.

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Greenville : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Franklin : Advanced Neurosciences Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Cordova : Neurology Clinic, P.C.

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Cordova : Neurology Clinic, P.C.

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Cordova : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Cordova : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Cordova : Teva Investigational Site 10313

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Franklin : Synthon investigational site 137

Efficacy and Safety of GTR in Comparison to Copaxone®

Franklin : Advanced Neurosciences Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Knoxville : New Orleans Center for Clinical Research (NOCCR)

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Knoxville : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Nashville : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nashville : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Nashville : Teva Investigational Site 10318

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Amarillo : Texas Oncology

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Austin : Future Search Trials of Neurology, LP

A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Austin : Future Search Trials of Neurology, LP

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Dallas : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Dallas : Baylor Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Dallas : University of Texas Southwestern

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Dallas : UT Southwestern

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Houston : Baylor College of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Houston : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Round Rock : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Round Rock : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Round Rock : Central Texas Neurology Consultants, P.A.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Round Rock : Central Texas Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

San Antonio : Osmotica Study Site-112

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

San Antonio : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

San Antonio : Integra Clinical Research, LLC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Sherman : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Sherman : Texoma Neurology Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Salt Lake City : Rocky Mountain MS Clinic

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

Salt Lake City : Rocky Mountain MS Clinic

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

Salt Lake City : Osmotica Study Site-133

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Salt Lake City : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Salt Lake City : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Salt Lake City : Rocky Mountain MS Clinic

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Burlington : Fletcher Allen Health Care - Neurology Service

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Charlottesville : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlottesville : Synthon investigational site 122

Efficacy and Safety of GTR in Comparison to Copaxone®

Henrico : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Henrico : Neurological Associates

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Newport News : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newport News : Hampton Roads Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Norfolk : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Roanoke : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Roanoke : Teva Investigational Site 10311

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Vienna : MS Center of Greater Washington

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lynnwood : Clinical Trials of America, Inc

Are you a man or woman over 18, and suffering from spasticity due to multiple sclerosis?

Seattle : Benaroya Research Institute at Virginia Mason

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Issaquah : Swedish Neuroscience Institute

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Kirkland : MS Center at Evergreen Health

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

Kirkland : MS Center at Evergreen

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Kirkland : MS Center at Evergreen Hospital

Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis

Mountlake Terrace :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Seattle : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Seattle :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Seattle : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Seattle : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Seattle : Swedish Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Seattle : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Seattle : Pacific Medical Centers

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Seattle : Swedish Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Seattle : Swedish Neuroscience Institute

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Seattle : MS Hub

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Tacoma : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tacoma : MultiCare Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tacoma : MultiCare Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Morgantown : United BioSource Corporation

Pregnancy Exposure Registry for Tysabri

Green Bay : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milwaukee : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Buenos Aires : Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Buenos Aires : Hospital Churruca-Visca

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Capital Federal : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Ciudad Autonoma de Buenos Aires : Hospital Britanico de Buenos Aires

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autonoma de Buenos Aires : Instituto de Neurologia Cognitiva

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autonoma de Buenos Aires : Medeos - Centro de Medicina Integral e Investigación Clínica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autónoma de Buenos Aires : Hospital Italiano

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad de Buenos Aires : Instituto Argentino de Investigacion Neurologica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Guaymallen : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Salta : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

San Miguel de Tucumán : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Randwick : GSK Investigational Site

GSK239512 DDI Study

Linz : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Vienna : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Vienna : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bitebsk : Synthon investigational site 401

Efficacy and Safety of GTR in Comparison to Copaxone®

Gomel : Synthon investigational site 402

Efficacy and Safety of GTR in Comparison to Copaxone®

Grodno : Synthon investigational site 403

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Synthon investigational site 407

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Synthon investigational site 408

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Synthon investigational site 404

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Vitebsk : Synthon investigational site 405

Efficacy and Safety of GTR in Comparison to Copaxone®

Antwerpen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brabant Wallon : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brussels : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bruxelles : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Edegem : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Hainaut : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

La Louviere : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Liege :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Liège : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Limburg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Luxembourg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Melsbroek : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oost-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Overpelt : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sijsele : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

West-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Banja Luka : Synthon investigational site 486

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Mostar : Teva Investigational Site 69008

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Sarajevo : Synthon investigational site 487

Efficacy and Safety of GTR in Comparison to Copaxone®

Sarajevo : Teva Investigational Site 69006

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Tuzla : Synthon investigational site 488

Efficacy and Safety of GTR in Comparison to Copaxone®

Pleven : Synthon investigational site 207

Efficacy and Safety of GTR in Comparison to Copaxone®

Plovdiv : Synthon investigational site 206

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 205

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 208

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 202

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 203

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Sofia : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Varna : Synthon investigational site 201

Efficacy and Safety of GTR in Comparison to Copaxone®

Bracebridge : South Muskoka Medical Clinic

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Burlington : Central Contact

Canadian Avonex PEN Productivity Study

Calgary : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edmonton : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edmonton : University of Alberta

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Gatineau : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Greenfield Park : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halifax : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halifax : Dalhousie MS Research Unit

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Kingston : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : London Health Sciences Centre

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Montreal : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montreal : Novartis Investigative Site Updated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Montreal : McGill University - MNI

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Ottawa : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ottawa : The Ottawa Hospital

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Saint John : Saint John Regional Hospital

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Toronto : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Toronto : Sunnybrook Health Sciences Centre

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Vancouver : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Vancouver : Vancouver Coastal Health: University of British Columbia Hospital

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Vancouver : MS Clinic UBC Hospital

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Victoria :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Many locations :

China Betaferon Adherence, Coping and Nurse Support Study

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica

Barranquilla : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Bogotá : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Medellin : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Osijek : Synthon investigational site 477

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : Synthon investigational site 478

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : Synthon investigational site 476

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : Synthon investigational site 475

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Brno : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Brno : Synthon investigational site 217

Efficacy and Safety of GTR in Comparison to Copaxone®

Brno : Synthon investigational site 211

Efficacy and Safety of GTR in Comparison to Copaxone®

Brno : Fakultni nemocnice u sv. Anny v Brne

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Brno : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Hradec Kralove : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hradec Kralove : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Hradec Kralove : Fakultni nemocnice Hradec Kralove

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Jihlava : Nemocnice Jihlava, prispevkova organizace

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Jihlava : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Jihlava : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Katowice : Synthon investigational site 240

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Olomouc : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Olomouc : Synthon investigational site 210

Efficacy and Safety of GTR in Comparison to Copaxone®

Olomouc :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Ostrava : Synthon investigational site 212

Efficacy and Safety of GTR in Comparison to Copaxone®

Ostrava : Fakultni Nemocnice Ostrava

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pardubice : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Praha : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Praha : Synthon investigational site 216

Efficacy and Safety of GTR in Comparison to Copaxone®

Praha : Synthon investigational site 215

Efficacy and Safety of GTR in Comparison to Copaxone®

Praha 2 : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Praha 2 : Vseobecna fakultni nemocnice v Praze

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Teplice : Synthon investigational site 214

Efficacy and Safety of GTR in Comparison to Copaxone®

Arthus C : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Esbjerg : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Esbjerg : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Esbjerg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Glostrup : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Glostrup : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

København Ø : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Odense : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sønderborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Vejle : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Vejle : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Viborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Kohtla-Jarve : Synthon investigational site 297

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Paernu : Teva Investigational Site 55005

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Tallinn : Synthon investigational site 296

Efficacy and Safety of GTR in Comparison to Copaxone®

Tallinn : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Tallinn : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Tallinn : Teva Investigational Site 55006

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Helsinki : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Helsinki : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Helsinski : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jyväskylä : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jyväskylä : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Tampere : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampere : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Turku : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Turku : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Turku : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Amiens cedex : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Angers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Annemasse : Etablissement Français du Sang Rhône Alpes - 1 route de Taninges

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population

Bordeaux : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux. Updated

Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis

Bron cedex : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Creteil : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Marseille :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Marseille : La Timone University Hospital (APHM)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Marseille cedex 5 : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Montpellier : Novartis Investigative Site

FTY720 in Patients With Primary Progressive Multiple Sclerosis

Montpellier cedex 5 : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nancy : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nantes : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nice : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Paris : La Pitie-Salpaetriere Hospital (APHP)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Poissy : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Reims : Maison Blanche Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Rennes : Rennes University Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Toulouse : Purpan Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Toulouse cedex 9 : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tourcoing : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tbilisi : Synthon investigational site 527

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 528

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 530

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 529

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 526

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Tbilisi : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Aachen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Aachen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Aalen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Abensberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Achim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Achim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Altenburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Altenholz-Stift : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Altenholz-Stift : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Alzenau : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Alzenau : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Alzenau : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Alzenau : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Andernach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Asbach : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Aschaffenburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Aschaffenburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Aschaffenburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Augsburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Augsburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Homburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Honnef : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bad Honnef : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Krozingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Mergentheim : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bad Mergentheim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bad Mergentheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Neustadt / Saale : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bad Saarow : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bad Saarow : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Wilbad : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bad Wildbad : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Baesweiler : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bamberg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bamberg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bamberg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Bamberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bamberg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bayreuth : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bayreuth : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Berlin : Charité Universitätsmedizin

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Berlin : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Berlin : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Berlin : Synthon investigational site 221

Efficacy and Safety of GTR in Comparison to Copaxone®

Berlin : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Berlin : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Berlin : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Berlin : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Berlin : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Berlin : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Berlin : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bielefeld : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bielefeld : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bielefeld : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Böblingen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Böblingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bochum : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Bochum : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bochum : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bochum : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bochum : Research Site

Fampridine Pregnancy Exposure Registry

Bochum : Novartis Investigative Site

Pregnancy Registry Trial

Bochum : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bogen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bonn : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Bonn : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Borna : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bottrop : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bremen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bremerhaven : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bremerhaven : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Buchholz : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Buchholz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Butzbach : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Butzbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Celle : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Chemnitz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Darmstadt : Please contact the Merck Communications Service for Recruiting locations

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

Dillingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Dortmund : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Dortmund : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Dresden : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Dresden : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Dresden : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Dresden : Synthon investigational site 220

Efficacy and Safety of GTR in Comparison to Copaxone®

Dresden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Duesseldorf : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Duesseldorf : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Duesseldorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Düren : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Düsseldorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Düsseldorf : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Eltville : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Emden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Emmendingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erbach : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Erbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erfurt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Erfurt : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erlangen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Erlangen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Essen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Essen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Flensburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Frankfurt : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Frankfurt : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Frankfurt am Main : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Freiburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Freiburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Fulda : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Geldern : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gelnhausen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gelsenkirchen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gilching : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gladbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Göttingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Greifswald : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Grevenbroich : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Grevenbroich : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gummersbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hagen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Halle : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halle (Saale) : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Halle/S. : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hamburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Hamburg : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Hamburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hamburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hannover : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Hannover : Synthon investigational site 224

Efficacy and Safety of GTR in Comparison to Copaxone®

Hannover : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hannover : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Heidelberg : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Heidelberg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Heidelberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Heidenheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Heidenheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hennigsdorf : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Herdecke : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Herford : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Herford : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hoppegarten : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Itzehoe : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Jena : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Jena : Synthon investigational site 227

Efficacy and Safety of GTR in Comparison to Copaxone®

Jena : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Juelich : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kaltenkirchen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kandel : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kassel : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kassel : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Kassel : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Kassel : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kastellaun : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Kastellaun : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Kastellaun : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Klingenmünster : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Klingenmünster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Koeln : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Koeln-Longerich : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Köln : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Köln : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Königsbrück : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Königsbrück : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Korbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Krefeld : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Landshut : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lappersdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Leipzig : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Leipzig : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Leipzig : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Leipzig : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Leverkusen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lohr am Main : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Lohr am Main : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Ludwigshafen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lüneburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lutherstadt Eisleben : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Magdeburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Mannheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Mannheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Many Locations :

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Many Locations : Updated

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Marburg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Merzig : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Mönchengladbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Muenchen : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Muenchen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Muenster : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Muenster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Mülheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

München : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

München : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Münster : Klinik und Poliklinik für Neurologie

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Münster : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Münster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Münster : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Nagold : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neuberg : Research Site

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Neuburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neuruppin : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neusäß : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neu-Ulm : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Nienburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Nümbrecht : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oberhausen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oldenburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oldenburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Osnabrück : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Osnabrück : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Osnabrueck : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Ostfildern : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Ostfildern : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Paderborn : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Pforzheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Potsdam : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Potsdam : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Potsdam : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Prien : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Prien : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Quakenbrück : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Ravensburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Regensburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Regensburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Remscheid : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Roesrath : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Rostock : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Rostock : Synthon investigational site 222

Efficacy and Safety of GTR in Comparison to Copaxone®

Rostock : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Rostock : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Rostock : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Rüdersdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Saarbrücken : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Schwalmstadt-Treysa : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Siegen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Siegen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Siegen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Singen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Sinsheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Sinsheim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Sinsheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stade : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stadtroda : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Stadtroda : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stuttgart : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Stuttgart : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Stuttgart : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Telgte : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Telgte : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Teupitz : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Teupitz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Troisdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Tübingen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Tübingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Tuebingen : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ulm : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Ulm : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Ulm : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Ulm : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Unterhaching : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Unterhaching : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Unterhaching : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wasserburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Weil am Rhein : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wendlingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wermsdorf : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Wermsdorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wermsdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Westerstede : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wiesbaden : Neurologisches Studienzentrum an der Stiftung Deutsche Klinik für Diagnostik GmbH

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Wiesbaden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wolfratshausen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Würzburg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Würzburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Zwickau : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Budapest : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Budapest : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Veszprem : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Dublin : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jerusalem : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Ramat Gan : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ancona : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Ancona : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Baggiovara : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bari : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bari : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Barletta : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Bergamo : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Biella : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Bolzano : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Caltanissetta : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Catania : Synthon investigational site 238

Efficacy and Safety of GTR in Comparison to Copaxone®

Catania : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Catania : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Catanzaro : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Cefalu : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cefalu : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Cefalù : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Chieti : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Como : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Coppito : Synthon investigational site 234

Efficacy and Safety of GTR in Comparison to Copaxone®

Cuneo : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Empoli : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Firenze : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Florence : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Foggia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Gallarate : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gallarate : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Genova : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Genova : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Imperia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

L'Aquila : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Lecce : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Legnago : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Livorno : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Messina : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Messina : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Milan : Institute of Experimental Neurology

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

Milano : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milano : Synthon investigational site 233

Efficacy and Safety of GTR in Comparison to Copaxone®

Milano : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Milano : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Modena : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Montichiari : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Monza : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Naples : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Naples : Investigational Site

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Napoli : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Napoli : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Novara : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Palermo : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Palermo : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pavia : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pavia : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Perugia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pisa : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pozzilli : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Reggio Calabria : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Roma : Research Site

Dose-finding Study of MT-1303

Roma : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Roma : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Rome : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Rome : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

San Donato Milanese : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Trieste : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Verona : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Chiba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Chiba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Fukuoka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Fukuoka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Hiroshima, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Hiroshima, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kawagoe, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kawagoe, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kodaira, : University of British Columbia

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kodaira, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kyoto, : London Health Sciences Centre

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Morioka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Morioka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Niigata, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Niigata, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Osaka, : Univ of Calgary / Foothills MC

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sapporo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sapporo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sendai, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sendai, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Suita, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Suita, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokorozawa, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokorozawa, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokyo : Research Site

An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Tokyo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokyo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tsukuba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tsukuba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Ube, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Ube, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Yokohama, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Yokohama, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Amman : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Riga : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Riga : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Riga : Teva Investigational Site 56005

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Beirut : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Kaunas : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Klaipeda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Kuala Lumpur : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Penang : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Chihuahua : Synthon investigational site 518

Efficacy and Safety of GTR in Comparison to Copaxone®

Culiacan : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Guadalajara : Synthon investigational site 516

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Mexico : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Mexico City : Synthon investigational site 514

Efficacy and Safety of GTR in Comparison to Copaxone®

Monterrey : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Morelia : Synthon investigational site 515

Efficacy and Safety of GTR in Comparison to Copaxone®

San Luis de Potosi : Synthon investigational site 522

Efficacy and Safety of GTR in Comparison to Copaxone®

San Luis Potosí : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Tijuana : Hospital Angeles

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

Chisinau : Synthon investigational site 547

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 550

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 549

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 548

Efficacy and Safety of GTR in Comparison to Copaxone®

Amsterdam : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Amsterdam : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Amsterdam : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Breda : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Breda : Amphia Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Eindhoven : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Gouda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hertogenbosch : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hoorn : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Leeuwarden : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nieuwegein : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nieuwegein : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Sittard : Maasland Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Sittard : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Sittard-Geleen : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Bergen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lørenskog : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Molde : Molde Hospital

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Oslo : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Stavanger : Stavanger University Hospital

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Panama City : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Jesus Maria : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

La Perla : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

San Isidro : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Bialystok : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bialystok : Synthon investigational site 244

Efficacy and Safety of GTR in Comparison to Copaxone®

Bialystok :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Czeladz :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Czeladz : Szpital Powiatowy w Czeladzi

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Gdansk : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gdansk : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Jaroslaw : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Katowice : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Katowice : Synthon investigational site 242

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice : Synthon investigational site 245

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice : Synthon investigational site 241

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Katowice : Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Diagnomed Clinical Research Sp. z.o.o.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Kielce :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Konskie : Zespol Opieki Zdrowotnej w Konskich

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Konstancin-Jeziorna :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Krakow : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Krakow :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Krakow : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Lodz : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lodz : Synthon investigational site 247

Efficacy and Safety of GTR in Comparison to Copaxone®

Lodz :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Lublin : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lublin : Synthon investigational site 251

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

Olsztyn : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Olsztyn : Synthon investigational site 243

Efficacy and Safety of GTR in Comparison to Copaxone®

Plewiska : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Plewiska : Specjalistyczny Gabinet Neurologiczny

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Poznan : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Poznan : Synthon investigational site 248

Efficacy and Safety of GTR in Comparison to Copaxone®

Poznan : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Poznan : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Szczecin : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Szczecin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Szczecin : Osrodek Badan Klinicznych Indywidualnej Specjalistycznej Praktyki Lekarskiej

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Szczecin : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Warsaw : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Warszawa : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Warszawa : Synthon investigational site 246

Efficacy and Safety of GTR in Comparison to Copaxone®

Warszawa :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Warszawa-Miedzylesie : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Wroclaw : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Wroclaw : Synthon investigational site 249

Efficacy and Safety of GTR in Comparison to Copaxone®

Lisboa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lisbon : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Porto : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Guaynabo : Caribbean Center for Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Bucharest : Synthon investigational site 264

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 263

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 262

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 260

Efficacy and Safety of GTR in Comparison to Copaxone®

Cluj-Napoca : Synthon investigational site 266

Efficacy and Safety of GTR in Comparison to Copaxone®

Arkhangelsk : Synthon investigational site 438

Efficacy and Safety of GTR in Comparison to Copaxone®

Barnaul : Synthon investigational site 435

Efficacy and Safety of GTR in Comparison to Copaxone®

Belgorod : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Belgorod : Synthon investigational site 437

Efficacy and Safety of GTR in Comparison to Copaxone®

Ekaterinburg : Synthon investigational site 431

Efficacy and Safety of GTR in Comparison to Copaxone®

Kaluga : Synthon investigational site 445

Efficacy and Safety of GTR in Comparison to Copaxone®

Kazan : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kazan : Synthon investigational site 427

Efficacy and Safety of GTR in Comparison to Copaxone®

Kemerovo : Synthon investigational site 432

Efficacy and Safety of GTR in Comparison to Copaxone®

Kirov : Synthon investigational site 447

Efficacy and Safety of GTR in Comparison to Copaxone®

Krasnoyarsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lipetsk : Synthon investigational site 446

Efficacy and Safety of GTR in Comparison to Copaxone®

Moscow : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Moscow : Synthon investigational site 571

Efficacy and Safety of GTR in Comparison to Copaxone®

Moscow : Osmotica Study Site-502

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Moscow : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Moscow : Teva Investigational Site 50124

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Nizhniy Novgorod : Synthon investigational site 428

Efficacy and Safety of GTR in Comparison to Copaxone®

Nizhniy Novgorod : Synthon investigational site 429

Efficacy and Safety of GTR in Comparison to Copaxone®

Novosibirsk : Synthon investigational site 442

Efficacy and Safety of GTR in Comparison to Copaxone®

Novosibirsk : Synthon investigational site 434

Efficacy and Safety of GTR in Comparison to Copaxone®

Penza : Synthon investigational site 444

Efficacy and Safety of GTR in Comparison to Copaxone®

Pyatigorsk : Synthon investigational site 433

Efficacy and Safety of GTR in Comparison to Copaxone®

Samara : Synthon investigational site 424

Efficacy and Safety of GTR in Comparison to Copaxone®

Smolensk : Synthon investigational site 420

Efficacy and Safety of GTR in Comparison to Copaxone®

St Petersburg : Osmotica Study Site-507

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

St. Petersburg : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

St. Petersburg : Osmotica Study Site-503

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

St. Petersburg : Osmotica Study Site-505

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

St.Petersburg : Synthon investigational site 430

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 440

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 426

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 421

Efficacy and Safety of GTR in Comparison to Copaxone®

Tomsk : Synthon investigational site 422

Efficacy and Safety of GTR in Comparison to Copaxone®

Tver : Synthon investigational site 441

Efficacy and Safety of GTR in Comparison to Copaxone®

Tyumen : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tyumen : Synthon investigational site 425

Efficacy and Safety of GTR in Comparison to Copaxone®

Ufa : Synthon investigational site 423

Efficacy and Safety of GTR in Comparison to Copaxone®

Volgograd : Synthon investigational site 443

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Belgrade : Synthon investigational site 451

Efficacy and Safety of GTR in Comparison to Copaxone®

Belgrade : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Kragujevac : Synthon investigational site 453

Efficacy and Safety of GTR in Comparison to Copaxone®

Novi Sad : Synthon investigational site 452

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Cape Town : Synthon investigational site 501

Efficacy and Safety of GTR in Comparison to Copaxone®

Durban : Synthon investigational site 505

Efficacy and Safety of GTR in Comparison to Copaxone®

Pretoria : Synthon investigational site 502

Efficacy and Safety of GTR in Comparison to Copaxone®

Badalona : Hospital Germans Trias i Pujol

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Barcelona : Hospital de la Santa Creu i Sant Pau

A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Barcelona : Hospital Clinic i Provincial

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital Vall d'Hebrón

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital del Mar

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Novartis Investigative Site

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

Barcelona : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Barcelona : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Barcelona : Hospital Vall D´Hebron

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Barcelona : Hospital del Mar

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Barcelona : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

El Palmar : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

El Palmar : Hospital Universitario Virgen de la Arrixaca

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Girona : Hospital Universitari Josep Trueta

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Girona : Hospital Universitari de Girona Dr. Josep Trueta

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Madrid : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Madrid : Hospital Universitario 12 de Octubre

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario Puerta del Hierro

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Clínico San Carlos

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario La Princesa

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario La Paz

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Research Site

Dose-finding Study of MT-1303

Madrid : Teva Investigational Site 31031

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Majadahonda : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Majadahonda (Madrid) : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Malaga : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Malaga : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Málaga : Hospital Regional Universitario Carlos Haya

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Santa Cruz de Tenerife : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Santiago de Compostela : Complexo Hospitalario Universitario de Santiago

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Sevilla : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sevilla : Hospital Universitario Vírgen Macarena

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Sevilla : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Valencia : Hospital Universitario La Fe

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Vigo : Hospital Xeral Vigo

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Göteborg : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Göteborg : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Örebro : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Stockholm : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Stockholm : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Stockholm : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Umeå : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bern : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lausanne : Centre Hospitalier Universitaire Vaudois - Dpt of Clinical Neurosciences - Neurology /Batiment 10-131 - Rue du Bugnon 46 -

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease

Lausanne : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lugano : Ospedale Regionale di Lugano - Civico

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Lugano : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

St. Gallen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Zug : Biogen Idec International GmbH, Global Medical Affairs

TOP: IMA-06-02 Tysabri Observational Program

Zurich : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Sfax : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tunis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ankara : Novartis Investigative Site

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Cherkassy : Synthon investigational site 474

Efficacy and Safety of GTR in Comparison to Copaxone®

Chernihiv : Synthon investigational site 459

Efficacy and Safety of GTR in Comparison to Copaxone®

Chernivtsi : Synthon investigational site 463

Efficacy and Safety of GTR in Comparison to Copaxone®

Dnepropetrovsk : Synthon investigational site 458

Efficacy and Safety of GTR in Comparison to Copaxone®

Dnepropetrovsk : Synthon investigational site 472

Efficacy and Safety of GTR in Comparison to Copaxone®

Donetsk : Synthon investigational site 468

Efficacy and Safety of GTR in Comparison to Copaxone®

Donetsk : Synthon investigational site 464

Efficacy and Safety of GTR in Comparison to Copaxone®

Ivano-Frankivsk : Synthon investigational site 495

Efficacy and Safety of GTR in Comparison to Copaxone®

Kharkiv : Synthon investigational site 469

Efficacy and Safety of GTR in Comparison to Copaxone®

Kharkiv : Synthon investigational site 461

Efficacy and Safety of GTR in Comparison to Copaxone®

Kiev : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Kyiv : Synthon investigational site 496

Efficacy and Safety of GTR in Comparison to Copaxone®

Kyiv : Synthon investigational site 456

Efficacy and Safety of GTR in Comparison to Copaxone®

Kyiv : Synthon investigational site 455

Efficacy and Safety of GTR in Comparison to Copaxone®

Lutsk : Synthon investigational site 473

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Synthon investigational site 462

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Synthon investigational site 497

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Synthon investigational site 466

Efficacy and Safety of GTR in Comparison to Copaxone®

Mariupol : Synthon investigational site 498

Efficacy and Safety of GTR in Comparison to Copaxone®

Odessa : Synthon investigational site 457

Efficacy and Safety of GTR in Comparison to Copaxone®

Poltava : Synthon investigational site 470

Efficacy and Safety of GTR in Comparison to Copaxone®

Simferopol : Synthon investigational site 467

Efficacy and Safety of GTR in Comparison to Copaxone®

Uzhhorod : Synthon investigational site 471

Efficacy and Safety of GTR in Comparison to Copaxone®

Vinnytsia : Synthon investigational site 465

Efficacy and Safety of GTR in Comparison to Copaxone®

Zhytomyr : Synthon investigational site 460

Efficacy and Safety of GTR in Comparison to Copaxone®

Brighton : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Brighton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Cambridge : GSK Investigational Site

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Edgbaston : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edinburgh : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Exeter : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hammersmith : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Irvine : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Liverpool : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : GSK Investigational Site

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

London : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : Research Site

Dose-finding Study of MT-1303

London : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

London : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Manchester : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Manchester : Morhosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Merck KGaA Communication Center for recruiting locations : Please conatact the

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Morriston : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newcastle Upon Tyne : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Norwich : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nottingham : GSK Investigational Site

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

Nottingham : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nottingham : MorphoSys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Plymouth : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Romford : GSK Investigational Site Updated

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Sheffield : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sheffield : Synthon investigational site 284

Efficacy and Safety of GTR in Comparison to Copaxone®

Stoke on Trent : Synthon investigational site 281

Efficacy and Safety of GTR in Comparison to Copaxone®

Torquay : Synthon investigational site 283

Efficacy and Safety of GTR in Comparison to Copaxone®

Truro : Synthon investigational site 280

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Multiple Sclerosis Clinical Trials

Alabama

Arizona

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maryland

Massachusetts

Michigan

Minnesota

Missouri

Montana

Nebraska

New Hampshire

New Jersey

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Albania

Argentina

Australia

Austria

Belarus

Belgium

Bosnia and Herzegovina

Bulgaria

Canada

China

Colombia

Croatia

Czech Republic

Denmark

Egypt

Estonia

Finland

France

Georgia

Germany

Greece

Hungary

Ireland

Israel

Italy

Japan

Jordan

Kazakhstan

Korea, Republic of

Kuwait

Latvia

Lebanon

Libyan Arab Jamahiriya

Lithuania

Malaysia

Mexico

Moldova, Republic of